Teva Announces New Strategic Focus in the Japanese Market
2020年7月30日 - 3:00PM
ビジネスワイヤ(英語)
- Japan Business Venture shifts focus to specialty assets and a
portfolio of select generics that meet patients' medical needs
- Remains positioned to address unmet patient needs in core
therapeutic areas
- Will divest majority of current non-differentiated generics
portfolio, as well as local manufacturing
- Business venture remains committed to serving its Japanese
patients and healthcare professionals
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), who
holds (through its Japanese affiliates) with Takeda a joint
business venture (the "BV") in the Japanese market, announced today
a new strategy for its local commercial operations. Nearly five
years since its inception, and following an in-depth review of
market opportunities, the BV's new strategy will focus on
commercializing a selection of complex generics, specialty assets
and other pipeline opportunities.
This shift will include a divestment of the majority of the BV's
generic and operational assets to Nichi-Iko Pharmaceutical Co.,
Ltd. This transaction is expected to close by early 2021.
The BV will retain approximately 20 generic molecules and
several pipeline assets, as well as its robust portfolio of
authorized generics, LLPs and specialty assets. The BV will seek to
address unmet patient needs with products from its portfolio and
pipeline and will continue to combine Teva’s deep marketing
expertise, commercial and medical excellence, coupled with
financial rigor, with Takeda’s leading brand reputation and strong
distribution presence in Japan.
Gianfranco Nazzi, Executive Vice President, International
Markets Commercial, said: "The Teva and Takeda business venture
has always aimed to address the wide-ranging needs of patients and
healthcare professionals in Japan. Our new strategy will allow each
of the parties to leverage its core strengths, and ultimately
better serve the Japanese patients. For Teva, and in line with the
company's strategic objectives, the new model presents a chance to
drive better performance by focusing our Japan business on a
portfolio of select generics and pipeline of specialty assets,
while continuing to put patients and healthcare professionals at
the center of our strategy."
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has
been developing and producing medicines to improve people’s lives
for more than a century. We are a global leader in generic and
specialty medicines with a portfolio consisting of over 3,500
products in nearly every therapeutic area. Around 200 million
people around the world take a Teva medicine every day and are
served by one of the largest and most complex supply chains in the
pharmaceutical industry. Along with our established presence in
generics, we have significant innovative research and operations
supporting our growing portfolio of specialty and biopharmaceutical
products. Learn more at www.tevapharm.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
re: our new strategic focus in the Japanese market, which are based
on management’s current beliefs and expectations and are subject to
substantial risks and uncertainties, both known and unknown, that
could cause our future results, performance or achievements to
differ significantly from that expressed or implied by such
forward-looking statements. Important factors that could cause or
contribute to such differences include risks relating to:
- the potential that the expected benefits and opportunities
related to our new strategic focus may not be realized or may take
longer to realize than expected;
- risks related to the satisfaction of the conditions to closing
the disposition of certain of our joint venture's generic and
operational assets (including the failure to obtain necessary
regulatory approvals) in the anticipated timeframe or at all,
including the possibility that the disposition does not close, and
the companies' ability to consummate the disposition on the terms
agreed by the parties;
- our ability to successfully compete in the marketplace,
including: competition from companies with greater resources and
capabilities; delays in launches of new products and our ability to
achieve expected results from investments in our product pipeline;
ability to develop and commercialize biopharmaceutical products;
efforts of pharmaceutical companies to limit the use of generics,
including through legislation and regulations and the effectiveness
of our patents and other measures to protect our intellectual
property rights;
- our substantial indebtedness, which may limit our ability to
incur additional indebtedness, engage in additional transactions or
make new investments, may result in a further downgrade of our
credit ratings; and our inability to raise debt or borrow funds in
amounts or on terms that are favorable to us;
- our business and operations in general, including: duration,
and geographic reach of the COVID-19 pandemic and its impact on our
business, financial condition, operations, cash flows, and
liquidity and on the economy in general; interruptions in our
supply chain, including due to potential effects of the COVID-19
pandemic on our operations and business in geographic locations
impacted by the pandemic and on the business operations of our
customers and suppliers; adequacy of and our ability to
successfully execute and maintain the activities and efforts
related to the measures we have taken or may take in response to
the COVID-19 pandemic and associated costs therewith;
implementation of our restructuring plan announced in December
2017; challenges associated with conducting business globally,
including adverse effects of the COVID-19 pandemic, political or
economic instability, major hostilities or terrorism; our ability
to attract, hire and retain highly skilled personnel; our ability
to develop and commercialize additional pharmaceutical products;
compliance with anti-corruption sanctions and trade control laws;
manufacturing or quality control problems; disruptions of
information technology systems; breaches of our data security;
variations in intellectual property laws; significant sales to a
limited number of customers; our ability to successfully bid for
suitable acquisition targets or licensing opportunities, or to
consummate and integrate acquisitions; our prospects and
opportunities for growth if we sell assets and potential
difficulties related to the operation of our new global enterprise
resource planning (ERP) system;
- compliance, regulatory and litigation matters, including:
increased legal and regulatory action in connection with public
concern over the abuse of opioid medications in the U.S. and our
ability to reach a final resolution of the remaining opioid-related
litigation; costs and delays resulting from the extensive
governmental regulation to which we are subject or delays in
governmental processing time including due to modified government
operations due to the COVID-19 pandemic and effects on product and
patent approvals; the effects of reforms in healthcare regulation
and reductions in pharmaceutical pricing, reimbursement and
coverage; governmental investigations into S&M practices;
potential liability for patent infringement; product liability
claims; increased government scrutiny of our patent settlement
agreements; failure to comply with complex Medicare and Medicaid
reporting and payment obligations; and environmental risks;
- other financial and economic risks, including: our exposure to
currency fluctuations and restrictions as well as credit risks;
potential impairments of our intangible assets; potential
significant increases in tax liabilities; and the effect on our
overall effective tax rate of the termination or expiration of
governmental programs or tax benefits, or of a change in our
business;
and other factors discussed in our Quarterly Report on Form 10-Q
for the first quarter of 2020 and our Annual Report on Form 10-K
for the year ended December 31, 2019, including in the sections
captioned "Risk Factors” and “Forward Looking Statements.”
Forward-looking statements speak only as of the date on which they
are made, and we assume no obligation to update or revise any
forward-looking statements or other information contained herein,
whether as a result of new information, future events or otherwise.
You are cautioned not to put undue reliance on these
forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200729006138/en/
IR Contacts United States Kevin C. Mannix (215)
591-8912
Israel Ran Meir 972 (3) 926-7516
PR Contacts United States Doris Li (973) 265-3752
Israel Yonatan Beker 972 (54) 888 5898
Teva Pharmaceutical Indu... (NYSE:TEVA)
過去 株価チャート
から 6 2024 まで 7 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
過去 株価チャート
から 7 2023 まで 7 2024